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OBJECTIVES: In the Survival of Myocardial Infarction Long-term Evaluation 4 
Study (SMILE-4) zofenopril (Z) associated with acetylsalicylic acid (ASA) was 
superior to ramipril (R) plus ASA in reducing the occurrence of major 
cardiovascular events, in patients with left ventricular dysfunction (LVD) 
following acute myocardial infarction (AMI). The present post-hoc analysis was 
performed to evaluate cost-effectiveness of Z compared to R. METHODS: A total 
of 771 patients with LVD and AMI were randomized, double-blind to Z 60 mg/day 
(n=389) or R 10 mg/day (n=382) plus ASA 100 mg/day and followed-up for 1 year. 
The primary study end-point was 1-year combined occurrence of death or 
hospitalization for cardiovascular causes. The economic analysis was based on 
the evaluation of cost of medications and hospitalizations and was applied to the 
intention-to-treat population (n=716). Cost data were drawn from the database of 
the Italian National Health Service. The incremental cost-effectiveness ratio 
(ICER) was used to quantify the cost per event prevented with Z versus R. 
RESULTS: Z significantly (p=0.028) reduced the risk of the primary study end-
point by 30% as compared to ramipril (95% confidence interval: 49%, 4%). The 
number needed to treat to prevent a major cardiovascular event with Z was 13 
less than with R. The cost of drug therapies was higher with Z (€313.90 per 
patient per year, n=365) than with R (€160.60 per patient per year, n=351). The 
cost related to the occurrence of major cardiovascular events requiring 
hospitalization, averaged €3195.47 for Z and €3071.37 for R. The ICER of Z versus 
R was €1990.88 per event prevented. CONCLUSIONS: Z is a viable and cost-
effective treatment for managing patients with LVD after AMI.  
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COST EFFECTIVENESS ANALYSIS OF TICAGRELOR IN THE TREATMENT OF 
PATIENTS WITH ACUTE CORONARY SYNDROME IN MEXICO: OUTCOMES FOR 
SPECIFIC GROUPS  
Polanco AC1, Ascencio ISI1, Almeida E2, Soto H3, Salazar A3 
1AstraZeneca, México, D. F., Mexico, 2Centro Médico Nacional Siglo XXI, D. F., Mexico, 3Iteliness 
Consulting, D. F., Mexico  
OBJECTIVES: To demonstrate the cost-effectiveness (CE) of ticagrelor in the 
treatment of Acute Coronary Syndrome (ACS) in specific population: invasive, 
Unstable Angina (UA), ST-elevation myocardial infarction (STEMI), non-STEMI 
(NSTEMI), and with or without diabetes. METHODS: Analysis of 
ticagrelor+acetylsalicylic acid (ASA) and clopidogrel/ASA as fixed dose 
combination (FDC) was made using results of PLATO study and its sub-studies. A 
Markov model was developed to evaluate each specific population at a time 
horizon of 14 years from an institutional perspective in Mexico. Life years gained 
(LY) was the outcome measure. An incremental cost-effectiveness ratio (ICER) 
was performed. Direct health care costs were used and a 5% discount rate was 
applied. A Sensitivity Analysis (SA) and Cost Effectiveness Acceptability Curve 
(CEAC) were performed. RESULTS: The ICERs of Ticagrelor+ASA versus 
clopidogrel/ASA for each specific population were: $4,647 for UA; $4,024 for Non-
STEMI; $4,128 for STEMI; $4,607 for Invasive-treatment and $4,672 for population 
without Diabetes. The best results are shown in the Diabetes groups with ICER 
$3,011. The results of SA were consistent with the base case. The likelihood of 
Ticagrelor+ASA to be cost-effective is 100% under the willingness-to-pay 
threshold in Mexico of one PIB per-capita ($10,064). CONCLUSIONS: 
Ticagrelor+ASA was CE compared with clopidogrel/ASA in all specific groups, 
especially in diabetes and NSTEMI patients. Therefore it could be considered as 
the first option for treating these patients in an institutional setting.  
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COST-EFFECTIVENESS OF NEWER ANTICOAGULANTS FOR STROKE 
PREVENTION IN ATRIAL FIBRILLATION: A SYSTEMATIC LITERATURE  
REVIEW  
Coleman CI1, Baker WL1, Limone BL2 
1University of Connecticut, Storrs, CT, USA, 2Hartford Hospital, Hartford, CT, USA  
OBJECTIVES: To conduct a systematic review of economic models of newer 
anticoagulants for stroke prevention in atrial fibrillation (SPAF). METHODS: We 
searched Medline, Embase, NHSEED and HTA databases and the Tuft’s Registry 
through October 10, 2012. Included models were cost-effectiveness analyses of 
newer agents for SPAF using a Markov or discrete event simulation model and 
published in English. RESULTS: Eighteen models were identified. Each was based 
on a lone randomized trial per new agent, and these trials were clinically and 
methodologically heterogeneous. Dabigatran 150mg, 110mg and sequential 
dosing were assessed in 9, 8, and 9 models, rivaroxaban in 4 and apixaban in 4. 
Warfarin was a first-line comparator in 94% of models. Models were conducted 
from the United States (44%), European countries (39%) and Canadian (17%) 
perspectives. In base-case analyses, patients typically were at moderate-risk of 
stroke, initiated anticoagulation at 65-73 years of age, and were followed for/near 
a lifetime. All models reported cost/quality-adjusted life-year, and while 22% 
reported using a societal perspective, no model included indirect costs. Four 
models reported an incremental cost-effectiveness ratio (ICER) for a newer 
anticoagulant (dabigatran 110mg (n=4)/150mg (n=2); rivaroxaban (n=1)) versus 
warfarin above commonly reported willingness-to-pay thresholds. ICERs 
(2012US$) versus warfarin ranged from $3,547-$86,000 for dabigatran 150mg, 
$20,713-$150,000 for dabigatran 110mg, $4,084-$21,466 for sequentially-dosed 
dabigatran and $23,065-$57,470 for rivaroxaban. Apixaban was demonstrated to 
be economically-dominant compared to aspirin, and dominant or cost-effective 
($11,400-$25,059) versus warfarin. Based on indirect comparisons, 3 models 
compared the cost-effectiveness of new agents and reported conflicting results. 
CONCLUSIONS: Cost-effectiveness models of newer anticoagulants for SPAF 
have been extensively published. They frequently found newer anticoagulants to 
be cost-effective, but due to the lack of head-to-head trials and the heterogeneity 
in clinical characteristic of underlying trials and modeling methods, it is 
currently unclear which of these newer agents is most cost-effective.  
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CLINICAL EFFECTIVENESS AND COST-EFFECTIVENESS OF RENAL 
DENERVATION FOR RESISTANT HYPERTENSION  
Kostyuk A, Tabarov A, Almadiyeva A 
National Center for Health Development, Astana, Kazakhstan  
OBJECTIVES: To assess the clinical effectiveness and cost-effectiveness of renal 
denervation (RDN) in resistant hypertensive patients. METHODS: Two reviewers 
independently screened titles and abstracts for eligibility. Studies eligible for 
inclusion in the systematic review of cost-effectiveness were full cost-
effectiveness analyses, cost-utility analyses, cost-benefit analyses and cost-
consequence analyses. One reviewer performed data extraction, which was 
checked by two reviewers independently. Two reviewers independently applied 
quality assessment criteria and differences in opinion were resolved at each 
stage. Studies were synthesized through a narrative review with full tabulation 
of the results of all included studies. Robustness and uncertainty were evaluated 
using deterministic and probabilistic sensitivity analyses. RESULTS: RDN 
substantially reduced event probabilities. Median survival increased for RDN 
compared to standard of care. RDN was cost-effective in comparison to standard 
of care in the reviewed published estimates of cost-effectiveness. These 
estimates can not be directly extrapolated to other settings due to potential 
variations in cost structures and different treatment patterns among countries 
that may influence final results. Findings were relatively insensitive to variations 
in input parameters except for systolic blood pressure reduction, baseline 
systolic blood pressure, and effect duration. Renal denervation gave improved 
outcomes. CONCLUSIONS: RDN appears to be a clinically effective and cost-
effective intervention in resistant hypertensive patients compared with standard 
of care. Literature review suggests that RDN, over a wide range of assumptions, 
is a cost-effective strategy for resistant hypertension that might result in lower 
cardiovascular morbidity and mortality. Uncertainties remain and further 
research in Kazakhstan is required to provide detailed data on patient QoL and 
cost effectiveness in the local setting.  
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OBJECTIVES: To demonstrate the cost-effectiveness of rosuvastatin 5mg in the 
treatment of adult patients with hypercholesterolemia in Mexico, from the 
institutional perspective. METHODS: A Markov model was developed in three 
age groups: 45-55, 56-65 and 66-75, at two time horizons: 20 years and lifetime. 
Comparators were: atorvastatin 20mg, pravastatin 10mg and simvastatin 20mg. 
The measure of efficacy was based on the Blassetto; and STELLAR; studies, while 
patient characteristics were adapted to Mexican population. The outcome 
measure was life years gained (LY); direct health care costs were used and 
express in US dollars; a 5% discount rate was applied; the estimated mean costs 
and LY were calculated and the results were presented as Incremental cost-
effectiveness ratios (ICERs). Sensitivity analyses were performed. RESULTS: In 
lifetime and in 20 years horizon simvastatin and atorvastatin were dominated by 
rosuvastatin 5mg that had ICERs bellow the willingness-to-pay threshold in 
Mexico of 1 PIB per-capita ($10,064). The sensitivity analysis showed consistency. 
Incremental LY for rosuvastatin 5mg vs pravastatin 10mg were 0.281; 0.282 and 
0.234 for the 3 groups of age respectively. Incremental costs were $406.60; 
$251.87 and 101.72 with ICERs of $1,447.44; $893.00 and $434.72 respectively. 
CONCLUSIONS: Rosuvastatin 5mg showed extensive dominance over 
simvastatin and atorvastatin. It is also cost-effectiveness compared with 
pravastatin with ICERs below the wiliness-to-pay threshold of one PIB per capita. 
The use of rosuvastatin 5mg in the treatment of Mexican patients with 
hypercholesterolemia in different groups of age for 20 years and life time 
horizons is cost-effective, particularly in the 56-65 and 66-75 groups with very 
low ICERs.  
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Parali E1, Ozdemir O2, Bozkurt K3, Demir M4, Ince B3, Kultursay H5, Ongen G3, Ongen Z3, 
Deger C1, Marmarali B1, Ozel MO1, Sumer F1, Tuna E1, Yilmaz ZS1 
1Bayer Turk Kimya San. Ltd. Sti., Istanbul, Turkey, 2Yorum Consultancy Ltd., Istanbul, Turkey, 
3Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey, 4Trakya University, 
Edirne, Turkey, 5Ege University Faculty of Medicine, Izmir, Turkey  
OBJECTIVES: To evaluate the cost-effectiveness of rivaroxaban versus o 
enoxaparin+warfarin in the treatment of DVT. METHODS: A Markov model 
simulating the progression of DVT in the course of three month cycles, up to 
death, was adapted to Turkish setting. The health states included the events 
related with recurrent DVT and bleeding. The model provides the comparison of 
six-month treatment with rivaroxaban against enoxaparin+warfarin. Event rates 
and the treatment effects of rivaroxaban were derived from EINSTEIN DVT 
clinical trial. Time horizons studied were 5 years and life-time. Utility values 
were based on the published literature. Local 2012 prices were used as source of 
the costs. The incremental cost-effectiveness ratios (ICER) were calculated with 
life-years (LYs) and quality-adjusted LYs (QALYs) gained. One-way sensitivity 
analyses were undertaken to examine the effects of model drivers. The analysis 
was undertaken from a payer perspective. Discount rate was set at 3.5% for both 
costs and outcomes. Mid-2012 USD currency rate was used. Willingness-to-pay 
(WTP) threshold was set as twice the local gross domestic product per capita 
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(US$20,888). RESULTS: The total cost of six-months treatment with rivaroxaban 
was US$89 and US$96* higher than warfarin. Increased drug cost (US$356) 
associated with rivaroxaban, was offset by reduced monitoring costs (US$239). 
Moreover, rivaroxaban was associated with LY increments of 0.006 and 0.026* 
years and QALY increments of 0.005 and 0.022* years. The ICERs were US$16,227 
and US$3,488* per LY gained and US$17,928 and US$4,056* per QALY gained. 
Sensitivity analysis showed that ICER value was sensitive only to the frequency 
of monitoring (between two to six-times a year) in warfarin patients. 
CONCLUSIONS: Rivaoxaban is cost-effective in the Turkish setting for the acute 
treatment of DVT patients, with ICERs below accepted WTP threshold across a 
range of conservative scenarios. * all pairs of figures correspond to 5-years and life-
time horizon, respectively.  
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A MODEL FRAMEWORK EVALUATING FACTORS AFFECTING THE VALUE OF 
TREATMENT ONE YEAR FOLLOWING AN ACUTE CORONARY SYNDROME EVENT  
Ariely R1, Klein R2, Gahn JC3, Tham WK2, Cohen D4, Bell C5, Tynan A6 
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OBJECTIVES: To build a flexible pharmacoeconomic model for early-stage 
analysis of interventions to prevent major adverse cardiovascular events 
(MACE=non fatal myocardial infarction (MI) and stroke, and cardiovascular 
death). METHODS: A literature search of cost-effectiveness models of 
cardiovascular disease interventions was conducted. Two models, one for heart 
disease and one for stroke, were selected as the framework (e.g., health states 
and transitions) for the development of an acute coronary syndrome (ACS) 
microsimulation model. Major parameter inputs were extracted from published 
literature. UK-based exploratory analyses using health state costs from the 
National Health System (NHS) reference costs and drug costs from the NHS 
October 2012 Electronic Drug Tariff, varied first-year risk of subsequent MACE 
events from 8-12%; and treatment efficacy (defined as a relative risk reduction 
(RRR)) from 15-25%. The base case treatment comparator was defined as 
standard of care (SoC) consistent with guidelines on secondary prevention of MI, 
including antihypertensive medications, aspirin, a statin, and one year of 
clopidogrel after each ACS event. New treatments can be added to, or substituted 
in the SoC. Age, gender, and patient history were varied for 10,000 individual 
patients simulated over specified timeframes. RESULTS: The model estimates a 
range of 15 to 39 MACE avoided per thousand patients in one year for a 15% RRR 
with an 8% background MACE rate versus a 25% RRR with a 12% background 
MACE rate, respectively. Assuming a £20,000/QALY willingness to pay in the UK, 
estimated lifetime incremental costs and QALYs predict the net benefit to be 
£1,371 for a point estimate of 20% RRR of a 10% background MACE rate. 
CONCLUSIONS: Early cost-effectiveness analyses using feasible RRRs in typical 
background MACE rates seen in ACS populations can be cost effective. Validation 
of this model framework can lead to more robust conclusions.  
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CLINICAL AND ECONOMIC CONSEQUENCES OF USING FONDAPARINUX OR 
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OBJECTIVES: Venous thromboembolism (VTE) causes significant impact on 
morbidity/mortality and economic burden to health systems. For preventing VTE 
in hip fracture/arthroplasty, the American College of Chest Physicians Practice 
Guidelines recommends the use of antithrombotic agents, such as fondaparinux 
and low-molecular weight heparin (LMWH). We present a cost-effectiveness 
analysis of fondaparinux versus enoxaparin for the prevention of VTE in hip 
surgery in Brazil. METHODS: A decision model was developed with a 180-day 
post-surgery horizon for the comparison of fondaparinux versus enoxaparin, 
both administered during hospitalization (average eight days) for the prophylaxis 
of VTE in hip surgery. Thromboembolic event and major bleeding probabilities 
were derived from three major published randomized clinical trials comparing 
fondaparinux and enoxaparin (N>6,000). Costs were calculated using 
microcosting technique in search for hip surgery and thrombotic/hemorrhagic 
complications reimbursed from the public Brazilian Unified Health System 
Database (DATASUS) in June 2012. Drug prices for antithrombotic prophylaxis 
were extracted from the Health Prices Database (BPS) in 2012 (1BRZ=0.52USD). 
RESULTS: VTE was observed in 5.9% versus 11.5% of patients with fondaparinux 
and enoxaparin, respectively (relative risk reduction=48.8%). Major bleeding 
(leading to death, reoperation or in critical sites) were similar in both groups, 
although bleeding with index >2 were more frequent in fondaparinux (2.4% 
versus 1.7%). Cost-effectiveness data showed fondaparinux was dominant over 
enoxaparin (i.e., reduced mortality at lower costs). There was an increment of 
three deaths per 1,000 patients by using enoxaparin instead of fondaparinux. 
Fondaparinux reported cost savings of BRZ16.53 per patient treated. Influence 
analysis showed that the incremental deaths and costs of enoxaparin were 
largely related to the higher incidence of thrombotic complications. 
CONCLUSIONS: Fondaparinux was found to be a cost-effective option under the 
Brazilian Public Health System perspective for the prophylaxis of VTE, resulting 
in lower mortality incidence at a reduced budget impact.  
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SYSTEMATIC REVIEW OF COST-EFFECTIVENESS ANALYSES OF DABIGATRAN 
VERSUS WARFARIN FOR ATRIAL FIBRILLATION ACROSS DIFFERENT HEALTH 
CARE SYSTEMS  
Jegathisawaran J1, Bowen JM1, Khondoker F1, Campbell K1, Burke N1, Goeree R1,  
Holbrook A2 
1PATH Research Institute, McMaster University, Hamilton, ON, Canada, 2St Joseph's Healthcare 
& Hamilton Health Sciences, Hamilton, ON, Canada  
OBJECTIVES: In the management of atrial fibrillation (AF), warfarin has been the 
anticoagulant of choice for preventing thrombotic complications, however, its 
need for regular blood test monitoring has led to the development of alternatives 
such as dabigatran. In order to address the variability and uncertainties in cost-
effectiveness and budget impact across jurisdictions, a systematic review of 
economic analyses was conducted. METHODS: A systematic review was 
conducted of economic evaluations published to November 2011 evaluating the 
cost-effectiveness of dabigatran versus warfarin for stroke prevention in AF. 
Databases searched included Ovid MEDLINE, EMBASE, the Cochrane Library and 
PubMed. The grey literature was also searched for relevant articles. For the 
purpose of a qualitative synthesis, details on the study design, data sources, cost 
effectiveness results (i.e. incremental cost effectiveness ratios (ICER)) were 
abstracted. Key factors influencing the cost-effectiveness of dabigatran 
compared with warfarin across different countries and health systems were 
identified. RESULTS: Seven economic evaluations comparing dabigatran and 
warfarin from four countries were identified. Costs, QALYs and ICERS were 
reported in all but one study. ICERs for dabigatran compared to warfarin ranged 
from £4,879.17 to $152,142.86 US, depending on the dabigatran dose and 
currency. Variations in ICERs occurred despite the fact that the efficacy and 
hemorrhage data were obtained from the same source, the RE-LY trial. Key 
factors identified between the models for variability in the results included 
differences in the costs of managing AF across countries; assumptions regarding 
warfarin monitoring frequency and costs, and INR control (trial-like or real-world 
setting); incorporation of baseline risk in relative rates of adverse events; and the 
costs of treating dabigatran-related hemorrhages without an antidote. 
CONCLUSIONS: Economic analyses for dabigatran versus warfarin have 
produced widely varying results. Real world effectiveness and safety data, 
including warfarin management practices, are useful to inform cost-
effectiveness in practice.  
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ECONOMIC EVALUATION OF APIXABAN FOR VENOUS THROMBOEMBOLISM IN 
TOTAL KNEE AND TOTAL HIP REPLACEMENT IN GUATEMALA  
Lutz MA1, Gordillo DI2, Bogantes JP1, Cuesta G3 
1Pfizer Central America and the Caribbean, San Jose, Costa Rica, 2Hospital Universitario 
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OBJECTIVES: . Due to the aging of the population, musculoskeletal diseases, 
particularly articular diseases and fragility fractures, have been constantly 
increasing. For this reason, total hip replacement (THR) and total knee 
replacement (TKR) have also increased. These procedures impact the quality of 
life and imply high risk of venous thromboembolism (VeT). VeT events have a 
high mortality in the elderly, 21% on hospitalized patients and up to 39% one 
year after the surgery. Prophylaxis for VeT is as a major strategy to minimize the 
consequences on patients undergoing TKR and THR. The aim of this study was to 
assess the cost-effectiveness (CE) of apixaban against dabigatran, rivaroxaban, 
fondaparinux, and enoxaparin for VeT prevention on these patients in 
Guatemala, from the private health care perspective. METHODS: . A simulated 
cohort of 1,000 patients subjected to THR/TKR entered a decision-tree model to 
compare costs and effectiveness of apixaban (2.5 mg/12 hours), dabigatran (220 
mg/day), rivaroxaban (10 mg/day), fondaparinux (2.5 mg/day) and enoxaparin (30 
mg/12 hours). Effectiveness measures were: total VeT events, bleeding rates and 
deaths. The model used a 5 year time horizon and only direct medical costs were 
considered (inpatient costs, medication expenses, adverse events, tests). 
Effectiveness and epidemiologic data were retrieved from published literature. 
Local costs (2012 US$) were gathered from the 3 private hospitals of Guatemala 
official databases. RESULTS: . The total VeT events were 69 for Apixaban, 55 for 
Rivaroxaban, 112 for Dabigatran, 86 for Enoxaparin and 45 for Fondoparinux. The 
estimated bleeds were 71 (Apixaban), 85 (Rivaroxaban), 85 (Dabigatran), 73 
(Enoxaparin) and 31 (Fondaparinux). Apixaban dominated enoxaparin and 
dabigatran while rivaroxaban and fondaparinux had an ICER of 
US$104,177/QALY and US$103,933/QALY, respectively. In the acceptability 
curves, Apixaban appeared with the highest probability of being cost-effective. 
CONCLUSIONS: . Apixaban resulted as the cost-effective therapy for VeT 
prevention for adult patients in Costa Rica.  
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COST-EFFECTIVENESS OF SAPIEN® TRANSCATHETER AORTIC VALVE FOR 
SEVERE SYMPTOMATIC AORTIC STENOSIS IN INOPERABLE PATIENTS IN THE 
BRAZILIAN PUBLIC HEALTH CARE SYSTEM  
Paladini L1, Nishikawa AM1, Lemos P2, Queiroga M2, Clark OAC1 
1Evidencias, Campinas, Brazil, 2Sociedade Brasileira de Hemodinâmica e Cardiologia 
Intervencionista (SBHCI), São Paulo, Brazil  
OBJECTIVES: Aortic stenosis is the most common valvular heart disease in the 
elderly - it is estimated that its prevalence is up to 5% in individuals over 75 
years. Its standard treatment is surgical valve replacement; however the surgical 
risk is very high for patients with advanced age and with the association of 
comorbidities. Thus, a significant proportion of patients become ineligible for 
this therapy. Treatment with transcatheter aortic valve implantation (TAVI) is a 
therapy with potentially lower risk peri-procedure and has been used as a 
therapeutic option in this group of patients considered inoperable. The aim of 
this study was to develop a cost-effectiveness analysis of the SAPIEN® valve 
implantation in patients with severe aortic stenosis who are not eligible for 
surgical treatment. METHODS: A Markov model was developed to compare the 
